Fed. Circ. Pushed To Ax Merck Antifungal Infringement Ruling
Xellia asked a Federal Circuit panel Monday to reverse a lower court's ruling that the company's generic version of anti-fungal medication Cancidas infringed Merck's patent, arguing the patent called for a...To view the full article, register now.
Already a subscriber? Click here to view full article